Effects of Aquamin F on NSAID Dose Reduction in Osteoarthritis of the Knee
Primary Purpose
Osteoarthritis of the Knee
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Aquamin F
Placebo (maltodextran)
Sponsored by
About this trial
This is an interventional treatment trial for Osteoarthritis of the Knee focused on measuring Osteoarthritis, Clinical trial, Aquamin F, NSAID
Eligibility Criteria
Inclusion Criteria:
- Subjects aged 35 to 75, male or female
- Subjects diagnosed with symptomatic moderate to severe osteoarthritis of the knee according to the modified criteria of the American College of Rheumatology 17,18
- Subjects who present with osteoarthritis of the knee as judged by symptoms and disabilities detectable through published, validated questionnaires or previous diagnosis by a physician
- subjects who are symptomatic with daily or near daily pain and stiffness from osteoarthritis
- subjects who are taking non-steroidal anti-inflammatory drugs (NSAIDs) prior to study enrollment
- subjects who are willing to stop NSAIDS and use acetaminophen for pain management during the trial
- subjects with screening WOMAC osteoarthritis index total score (transformed score) of not more than 75
- subjects with ability to comprehend and complete the questionnaires and forms
- subjects whose schedules permit clinical evaluations every four weeks
- subjects who are willing to stop taking calcium supplements, if any and to restrict consumption of high calcium food to 600mg (two dairy servings) per day
- subjects with a high probability of compliance with study procedures and test article consumption
- subjects willing and able to follow protocol guidelines and schedules and complete diaries
- subjects who are likely to abstain from taking unathorized supplements or participating in any other clinical trial or experimental treatment during this trial
- subjects with normal gastrointestinal digestion and absorption
Exclusion Criteria:
- subjects who have a history of inflammatory arthritis, gout, pseudogout, Paget's disease, seizure disorder, insulin dependent diabetes mellitus, uncontrolled hypertension, unstable cardiovascular disease, active hepatic or renal disease, active cancer and/or HIV infection
- subjects who are non-ambulatory or bedridden due to osteoarthritis
- subjects who are dependent on prescription drugs to control pain
- subjects on any other clinical trial or experimental treatment in the past 3 months
- subjects who are pregnant, lactating or at risk of becoming pregnant
- subjects who have received : intramuscular corticosteroid injection or systemic corticosteroid administration within 4 weeks prior to study enrollment, intra-articular corticosteroid injection within 2 months prior to study enrollment or intra-articular hyaluronic acid injection within 4 months prior to study enrollment.
Sites / Locations
- Minnesota Applied Research Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
1
2
Arm Description
Subjects were given Aquamin F
Subjects were given a maltodextran placebo
Outcomes
Primary Outcome Measures
WOMAC scores (pain, stiffness, mobility, total score)
6 minute walking distances
Active and Passive range of motion (goniometer measurements)
NSAID usage
Rescue medication (acetaminophen) usage
Secondary Outcome Measures
DXA scans for bone mineral density
CRP levels
Lipid profiles
the safety/toxicology measurements including a chemistry profile (including serum calcium)
complete blood counts
adverse events
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00755482
Brief Title
Effects of Aquamin F on NSAID Dose Reduction in Osteoarthritis of the Knee
Official Title
Randomised, Placebo Controlled Trial to Examine the Effect of Aquamin F on NSAID Dose Reduction in Subjects With Osteoarthritis of the Knee.
Study Type
Interventional
2. Study Status
Record Verification Date
September 2008
Overall Recruitment Status
Completed
Study Start Date
January 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
September 2006 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Marigot Ltd.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The objective of this trial is to evaluate the effect of Aquamin F versus placebo on NSAID (non-steroidal anti-inflammatory drug) dose reduction in subjects with osteoarthritis of the knee.
Hypothesis 1: After 12 weeks of treatment, subjects taking Aquamin F will use significantly less NSAID medications for symptoms of osteoarthritis versus placebo alone.
Hypothesis 2: No significant differences will be seen for adverse events between the subjects taking Aquamin F or placebo.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis of the Knee
Keywords
Osteoarthritis, Clinical trial, Aquamin F, NSAID
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
29 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Active Comparator
Arm Description
Subjects were given Aquamin F
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
Subjects were given a maltodextran placebo
Intervention Type
Drug
Intervention Name(s)
Aquamin F
Intervention Type
Drug
Intervention Name(s)
Placebo (maltodextran)
Primary Outcome Measure Information:
Title
WOMAC scores (pain, stiffness, mobility, total score)
Title
6 minute walking distances
Title
Active and Passive range of motion (goniometer measurements)
Title
NSAID usage
Title
Rescue medication (acetaminophen) usage
Secondary Outcome Measure Information:
Title
DXA scans for bone mineral density
Title
CRP levels
Title
Lipid profiles
Title
the safety/toxicology measurements including a chemistry profile (including serum calcium)
Title
complete blood counts
Title
adverse events
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Subjects aged 35 to 75, male or female
Subjects diagnosed with symptomatic moderate to severe osteoarthritis of the knee according to the modified criteria of the American College of Rheumatology 17,18
Subjects who present with osteoarthritis of the knee as judged by symptoms and disabilities detectable through published, validated questionnaires or previous diagnosis by a physician
subjects who are symptomatic with daily or near daily pain and stiffness from osteoarthritis
subjects who are taking non-steroidal anti-inflammatory drugs (NSAIDs) prior to study enrollment
subjects who are willing to stop NSAIDS and use acetaminophen for pain management during the trial
subjects with screening WOMAC osteoarthritis index total score (transformed score) of not more than 75
subjects with ability to comprehend and complete the questionnaires and forms
subjects whose schedules permit clinical evaluations every four weeks
subjects who are willing to stop taking calcium supplements, if any and to restrict consumption of high calcium food to 600mg (two dairy servings) per day
subjects with a high probability of compliance with study procedures and test article consumption
subjects willing and able to follow protocol guidelines and schedules and complete diaries
subjects who are likely to abstain from taking unathorized supplements or participating in any other clinical trial or experimental treatment during this trial
subjects with normal gastrointestinal digestion and absorption
Exclusion Criteria:
subjects who have a history of inflammatory arthritis, gout, pseudogout, Paget's disease, seizure disorder, insulin dependent diabetes mellitus, uncontrolled hypertension, unstable cardiovascular disease, active hepatic or renal disease, active cancer and/or HIV infection
subjects who are non-ambulatory or bedridden due to osteoarthritis
subjects who are dependent on prescription drugs to control pain
subjects on any other clinical trial or experimental treatment in the past 3 months
subjects who are pregnant, lactating or at risk of becoming pregnant
subjects who have received : intramuscular corticosteroid injection or systemic corticosteroid administration within 4 weeks prior to study enrollment, intra-articular corticosteroid injection within 2 months prior to study enrollment or intra-articular hyaluronic acid injection within 4 months prior to study enrollment.
Facility Information:
Facility Name
Minnesota Applied Research Center
City
Edina
State/Province
Minnesota
ZIP/Postal Code
55345
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
18279523
Citation
Frestedt JL, Walsh M, Kuskowski MA, Zenk JL. A natural mineral supplement provides relief from knee osteoarthritis symptoms: a randomized controlled pilot trial. Nutr J. 2008 Feb 17;7:9. doi: 10.1186/1475-2891-7-9.
Results Reference
background
PubMed Identifier
19187557
Citation
Frestedt JL, Kuskowski MA, Zenk JL. A natural seaweed derived mineral supplement (Aquamin F) for knee osteoarthritis: a randomised, placebo controlled pilot study. Nutr J. 2009 Feb 2;8:7. doi: 10.1186/1475-2891-8-7.
Results Reference
derived
Learn more about this trial
Effects of Aquamin F on NSAID Dose Reduction in Osteoarthritis of the Knee
We'll reach out to this number within 24 hrs